Göran Ahlgren

Fler filtreringsmöjligheter
  1. 2021
  2. Adaptive sequential plan-on-plan optimization during prostate-specific antigen response guided radiotherapy of recurrent prostate cancer

    Vilberg Jóhannesson, Elinore Wieslander, Per Nilsson, Eva Brun, Ulrika Bitzén, Göran Ahlgren, Tomas Olsson, Sven Bäck, Elisabeth Kjellén & Adalsteinn Gunnlaugsson, 2021, I: Physics and imaging in radiation oncology. 18, s. 5-10 6 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  3. Association of surgeon and hospital volume with short-term outcomes after robotassisted radical prostatectomy: Nationwide, population-based study

    Rebecka Arnsrud Godtman, Erik Persson, Walter Cazzaniga, Fredrik Sandin, Stefan Carlsson, Göran Ahlgren, Eva Johansson, David Robinsson, Jonas Hugosson & Pär Stattin, 2021, I: PLoS ONE. 16, 6 June 2021, e0253081.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  4. 2020
  5. PSA decay during salvage radiotherapy for prostate cancer as a predictor of disease outcome – 5 year follow-up of a prospective observational study

    Adalsteinn Gunnlaugsson, Elisabeth Kjellén, Ola Bratt, Göran Ahlgren, Vilberg Johannesson, René Blom & Per Nilsson, 2020, I: Clinical and Translational Radiation Oncology. 24, s. 23-28

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  6. 2019
  7. Population-based, nationwide registration of prostatectomies in Sweden

    Walter Cazzaniga, Rebecka Arnsrud Godtman, Stefan Carlsson, Göran Ahlgren, Eva Johansson, David Robinson, Jonas Hugosson & Pär Stattin, 2019, I: Journal of Surgical Oncology. 120, 4, s. 803-812

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  8. 2018
  9. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial

    Göran M. Ahlgren, Per Flodgren, Teuvo L.J. Tammela, Pirkko Kellokumpu-Lehtinen, Michael Borre, Anders Angelsen, Jon Reidar Iversen, Asgerdur Sverrisdottir, Eirikur Jonsson & Lisa Sengelov, 2018, I: European Urology. 73, 6, s. 870-876

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  10. 2017
  11. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study

    Frederik Birkebæk Thomsen, Fredrik Sandin, Hans Garmo, Ingela Franck Lissbrant, Göran Ahlgren, Mieke Van Hemelrijck, Jan Adolfsson, David Robinson & Pär Stattin, 2017, I: European Urology. 72, 6, s. 920-928

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  12. Long-term functional outcomes after radical cystectomy with ileal bladder substitute: does the definition of continence matter?

    Fredrik Liedberg, Göran Ahlgren, Gediminas Baseckas, Sigurdur Gudjonsson, Ulf Håkansson, Sara Lindquist, Annica Löfgren, Oliver Patschan, Carina Siller & Gottfrid Sjödahl, 2017, I: Scandinavian Journal of Urology. 51, 1, s. 44-49 6 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  13. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): An open-label, phase 3, randomised controlled trial

    Abdel Rahmène Azzouzi, Sébastien Vincendeau, Eric Barret, Antony Cicco, François Kleinclauss, Henk G. van der Poel, Christian G. Stief, Jens Rassweiler, Georg Salomon, Eduardo Solsona, Antonio Alcaraz, Teuvo T. Tammela, Derek J. Rosario, Francisco Gomez-Veiga, Göran Ahlgren, Fawzi Benzaghou, Bertrand Gaillac, Billy Amzal, Frans M J Debruyne, Gaëlle Fromont & 2 andra, Christian Gratzke & Mark Emberton, 2017, I: The Lancet Oncology. 18, 2, s. 181-191

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  14. Prostatacancercentrum - navet i framtidens prostatacancersjukvård

    Ola Bratt, Göran Ahlgren, Anna Carin Börjedahl, Ingela Franck Lissbrant & Calle Waller, 2017, I: Läkartidningen. 114, 5

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  15. 2016
  16. Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden

    Johanna Svensson, Emelie Andersson, Ulf Persson, Thomas Edekling, Anna Ovanfors & Göran Ahlgren, 2016 jul 3, I: Scandinavian Journal of Urology. 50, 4, s. 286-291

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  17. Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries

    Sophie D. Fosså, Thomas Bengtsson, Michael Borre, Göran Ahlgren, Antti Rannikko & Alv A. Dahl, 2016, I: Scandinavian Journal of Urology. 50, 5, s. 330-337 8 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  18. 2015
  19. (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.

    Henrik Kjölhede, Göran Ahlgren, Helen Almquist, Fredrik Liedberg, Kerstin Lyttkens, Thomas Ohlsson & Ola Bratt, 2015, I: World Journal of Urology. 33, 11, s. 1749-1752

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  20. Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe.

    Karim Fizazi, Per-Anders Abrahamsson, Göran Ahlgren, Joaquim Bellmunt, Daniel Castellano, Stephane Culine, Ronald de Wit, Silke Gillessen, Juergen E Gschwend, Freddie Hamdy, Nicholas James, Raymond McDermott, Kurt Miller, Thomas Wiegel, Manfred Wirth & Bertrand Tombal, 2015, I: European Urology. 67, 5, s. 904-912

    Forskningsoutput: TidskriftsbidragÖversiktsartikel

  21. Development of a standardised training curriculum for robotic surgery: a consensus statement from an international multidisciplinary group of experts

    Kamran Ahmed, Reenam Khan, Alexandre Mottrie, Catherine Lovegrove, Ronny Abaza, Rajesh Ahlawat, Thomas Ahlering, Göran Ahlgren, Walter Artibani, Eric Barret, Xavier Cathelineau, Ben Challacombe, Patrick Coloby, Muhammad S. Khan, Jacques Hubert, Maurice Stephan Michel, Francesco Montorsi, Declan Murphy, Joan Palou, Vipul Patel & 19 andra, Pierre-Thierry Piechaud, Hendrik Van Poppel, Pascal Rischmann, Rafael Sanchez-Salas, Stefan Siemer, Michael Stoeckle, Jens-Uwe Stolzenburg, Jean-Etienne Terrier, Joachim W. Thueroff, Christophe Vaessen, Henk G. Van der Poel, Ben Van Cleynenbreugel, Alessandro Volpe, Christian Wagner, Peter Wiklund, Timothy Wilson, Manfred Wirth, Joern Witt & Prokar Dasgupta, 2015, I: BJU International. 116, 1, s. 93-101

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  22. Salvage cryotherapy for local recurrence after radiotherapy for prostate cancer

    Klara Kvorning Ternov, Ane Krag Jakobsen, Ola Bratt & Göran Ahlgren, 2015, I: Scandinavian Journal of Urology. 49, 2, s. 115-119

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  23. 2014
  24. (18)F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer.

    Henrik Kjölhede, Göran Ahlgren, H Almquist, Fredrik Liedberg, Kerstin Lyttkens, Tomas G Ohlsson & Ola Bratt, 2014, I: World Journal of Urology. 32, 4, s. 965-970

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  25. 2013
  26. Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer

    Karolina Boman, Ulrika Segersten, Göran Ahlgren, Jakob Eberhard, Mathias Uhlén, Karin Jirström & Per Malmström, 2013 apr 8, I: BMC Urology. 13, April,8, s. 17 17.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  27. Low rate of lymphedema after extended pelvic lymphadenectomy followed by pelvic irradiation of node-positive prostate cancer

    Elisabeth Rasmusson, Adalsteinn Gunnlaugsson, René Blom, Thomas Bojrk-Eriksson, Per Nilsson, Göran Ahlgren, Charlotta Jönsson, Karin Johansson & Elisabeth Kjellén, 2013, I: Radiation Oncology. 8, 271.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  28. 2012
  29. Combined (18) F-fluorocholine and (18) F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.

    Henrik Kjölhede, Göran Ahlgren, Helen Almquist, Fredrik Liedberg, Kerstin Lyttkens, Tomas G Ohlsson & Ola Bratt, 2012, I: BJU International. 110, 10, s. 1501-1506

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  30. 2011
  31. NATION-WIDE POPULATION-BASED STUDY ON 15-YEAR MORTALITY IN PROSTATE CANCER ACCORDING TO RISK CATEGORIES IN THE NATIONAL PROSTATE CANCER REGISTER (NPCR) OF SWEDEN

    P. Stattin, F. Sandin, Göran Ahlgren, O. Bratt, J. E. Damber, J. Hugosson, B. Pettersson, D. Robinson, M. Tornblom, S. Karlsson, O. Andren, A. Bill-Axelson, A. Widmark, L. Egevad, Roy Ehrnström, J. Adolfsson, M. Lambe & J. E. Johansson, 2011, I: European Urology Supplements. 10, 2, s. 324-325

    Forskningsoutput: TidskriftsbidragPublicerat konferensabstract

  32. 2010
  33. System for interstitial photodynamic therapy with online dosimetry: first clinical experiences of prostate cancer.

    Johannes Swartling, Johan Axelsson, Göran Ahlgren, Karl Mikael Kälkner, Sten Nilsson, Sune Svanberg, Katarina Svanberg & Stefan Andersson-Engels, 2010, I: Journal of Biomedical Optics. 15, 5, 058003.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  34. 2009
  35. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.

    Ola Bratt, M Häggman, Göran Ahlgren, O Nordle, A Björk & J-E Damber, 2009, I: British Journal of Cancer. 101, s. 1233-1240

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  36. 2008
  37. 2007
  38. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 - Data from the national prostate cancer register in Sweden

    Jan Adolfsson, Hans Garmo, Eberhard Varenhorst, Göran Ahlgren, Christer Ahlstrand, Ove Andren, Anna Bill-Axelson, Ola Bratt, Jan-Erik Damber, Karin Hellstrom, Magnus Hellstrom, Erik Holmberg, Lars Holmberg, Jonas Hugosson, Jan-Erik Johansson, Bill Petterson, Magnus Tornblom, Anders Widmark & Par Stattin, 2007, I: Scandinavian Journal of Urology and Nephrology. 41, 6, s. 456-477

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  39. 2005
  40. The 5alpha-Reductase Type II A49T and V89L High-Activity Allelic Variants are More Common in Men with Prostate Cancer Compared with the General Population.

    Yvonne Giwercman, Per-Anders Abrahamsson, Aleksander Giwercman, Virgil Gadaleanu & Göran Ahlgren, 2005, I: European Urology. 48, Jul 20, s. 679-685

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  41. 2002
  42. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial

    G Aus, Per-Anders Abrahamsson, Göran Ahlgren, J Hugosson, S Lundberg, M Schain, S Schelin & K Pedersen, 2002, I: BJU International. 90, 6, s. 561-566

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  43. 1999
  44. Prognostic factors in prostate cancer with special reference to the effect of hormonal therapy

    Göran Ahlgren, 1999, Department of Urology, Malmö University Hospital, 205 02 Malmö, Sweden. 152 s.

    Forskningsoutput: AvhandlingDoktorsavhandling (sammanläggning)